SCHEMBL30049081

SCHEMBL30049081

O=C1OCCN1c1ccc(S(=O)(=O)N2CCC3(CCCN(Cc4ccccc4F)C3)CC2)cn1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 13/20 0.47
▸ CYP2D6 P10635 12/20 0.47
▸ TSHR P16473 9/20 0.47
▸ CYP2C19 P33261 8/20 0.45
▸ CYP1A2 P05177 7/20 0.45
▸ ALDH1A1 P00352 6/20 0.45
▸ USP2 O75604 6/20 0.45
▸ CYP2C9 P11712 6/20 0.45
▸ SMN1; SMN2 Q16637 6/20 0.43
▸ LMNA P02545 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ATM Q13315 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.39
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27162042 1.00 CYP3A4 (0.47) CYP3A4CYP2D6TSHRCYP2C19CYP1A2
SCHEMBL27162246 0.92 CYP3A4 (0.43) CYP3A4CYP2D6TSHRCYP2C19CYP1A2
SCHEMBL30050073 0.92 CYP3A4 (0.43) CYP3A4CYP2D6TSHRCYP2C19CYP1A2
SCHEMBL30049542 0.91 SMN1; SMN2 (0.40) CYP3A4CYP2D6TSHRCYP2C19CYP1A2
SCHEMBL27162591 0.91 SMN1; SMN2 (0.40) CYP3A4CYP2D6TSHRCYP2C19CYP1A2
SCHEMBL30050034 0.91 SMN1; SMN2 (0.43) CYP3A4CYP2D6TSHRCYP2C19ALDH1A1
SCHEMBL27162198 0.91 SMN1; SMN2 (0.43) CYP3A4CYP2D6TSHRCYP2C19ALDH1A1
SCHEMBL30050026 0.91 CYP3A4 (0.44) CYP3A4CYP2D6TSHRCYP2C19CYP1A2
SCHEMBL27161544 0.91 CYP3A4 (0.44) CYP3A4CYP2D6TSHRCYP2C19CYP1A2
SCHEMBL30050997 0.88 CYP2D6 (0.62) CYP3A4CYP2D6TSHRCYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 CYP3A4 497/4885CYP2D6 514/4885TSHR 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback